South Africa began rolling out Lenacapavir, a long-acting injectable HIV-prevention drug, in early June 2026 [1, 3].

The introduction of the drug addresses a critical gap for people who struggle with the adherence required for daily oral pre-exposure prophylaxis (PrEP). By reducing the frequency of doses, health officials aim to lower new infection rates among high-risk groups, including pregnant women [1, 5].

Lenacapavir requires only two injections per year [1]. The administration interval is once every six months [2]. This shift from a daily pill to a semi-annual injection is intended to remove barriers to consistent prevention.

"The drug offers hope for those who find daily oral medications challenging, requiring only one injection every six months," Emory University experts said [2].

Implementation of the program has seen differing reports regarding its scope. Some reports indicate a national rollout, while others state the distribution is geographically selective, targeting specific high-prevalence districts [1, 4]. This selective approach may prioritize areas with the highest immediate need.

Funding for the program remains a point of contention. Some sources indicate that U.S. aid cuts could threaten the program's impact, while others suggest the South African government expects domestic funding to be sufficient [1, 5].

"Lenacapavir could transform South Africa's fight against the HIV epidemic if enough doses are secured," NPR staff said [1].

The global health community has signaled support for the drug's integration into public health strategies. The World Health Organization said it now recommends that countries include lenacapavir as part of their HIV-prevention toolkit, especially for high-risk populations [6].

Mabalane Mfundisi, Executive Director of the Show-Me Your Number HIV prevention project, is among the officials overseeing the rollout to ensure the drug reaches those most in need [1].

“The drug offers hope for those who find daily oral medications challenging, requiring only one injection every six months.”

The shift toward long-acting injectables represents a pivot in HIV prevention strategy from patient-led daily adherence to provider-led clinical intervals. While the medical efficacy of Lenacapavir is high, the success of the South African rollout depends on resolving the tension between limited funding and the goal of widespread access. If the rollout remains geographically selective due to budget constraints, the drug may create a disparity in prevention access between high-prevalence districts and the rest of the country.